GDC-0032 is an investigational drug that works by inhibiting PI3 kinase (PI3K), an enzyme that fuels the growth of some types of cancer. Researchers are evaluating GDC-0032 alone and in combination with other therapies in patients with advanced cancer. GDC-0032 is a pill that is taken orally (by mouth).
In the phase I study, researchers are evaluating the safety and effectiveness of GDC-0032 in patients with advanced solid tumors that have extra copies of the PI3K gene.
In the phase II study, patients with breast cancer that is positive for the estrogen receptor and negative for HER2 which has continued to grow despite aromatase inhibitor therapy will receive GDC-0032 in combination with fulvestrant. Fulvestrant is already approved for the treatment of women with hormone receptor-positive breast cancer that continues to grow after hormonal therapy. It is given by injection.